A-Alpha Bio and LLNL expand collaboration with additional $2.4M in DoD funding
Almost exactly one year ago, we announced our first partnership with Lawrence Livermore National Laboratory (LLNL) to generate data and train machine learning (ML) models for the prediction of protein-protein interactions between antibodies and COVID-19 variants to increase the speed of therapeutic response to emerging strains. Based on the success of that work and with additional Department of Defense (DoD) / JPEO support, we have now expanded the collaboration beyond COVID-19 to other potential biothreats.
A-Alpha Bio will use AlphaSeq to measure millions of protein-protein interactions between antibodies and variants of pathogens identified as concerning by the DoD. These data will be used to train ML models and predict cross-reactive and strain specific binders for the acceleration of future drug discovery.
We are excited to continue working with the LLNL team and to applying our platforms and capabilities to a challenging and high-impact problem.
Coverage in the Puget Sound Business Journal can be read here.